Promising Results for New Endometrial Cancer Treatment in Phase 3 Trial

A novel treatment for endometrial cancer has shown significant promise in a Phase 3 clinical trial. Merck, the pharmaceutical company, revealed that the investigational drug sacituzumab tirumotecan (sac-TMT) successfully achieved its primary goals of overall survival and progression-free survival among patients with advanced or recurrent endometrial cancer.

According to Merck’s press release, the TroFuse-005 trial marks the first global Phase 3 study to present a notable improvement in survival rates compared to chemotherapy for these patients. Furthermore, sac-TMT is the first antibody-drug conjugate (ADC) to exhibit this achievement for endometrial cancer patients in such circumstances.

An ADC is a targeted cancer treatment designed to deliver medication directly to tumor cells while minimizing harm to healthy cells. The investigational drug, sac-TMT, is administered biweekly through intravenous infusion.

Involving a total of 776 patients, the trial included those whose condition had deteriorated after receiving both platinum chemotherapy and immunotherapy. Participants were randomly assigned to receive either sac-TMT or a physician-chosen treatment, including doxorubin or paclitaxel chemotherapy. Patients were informed of their respective treatment options.

Research found that those treated with sac-TMT experienced clinically significant improvement in comparison to those receiving physician-chosen therapies.

Merck reported that trial benchmarks for response rates were reached, and side effects mirrored those found in previous studies of sac-TMT. While specific statistics such as survival benefit and response rates remain undisclosed, researchers aim to present comprehensive Phase 3 data at an upcoming medical conference. Sac-TMT may address a critical unmet need for specific patients struggling with advanced endometrial cancer.

Dr. Domenica Lorusso, the study’s global lead investigator and professor at Humanitas University in Milan, emphasized the importance of these findings. She stated that sac-TMT may provide much-needed options for patients whose disease progresses despite prior platinum and immunotherapy treatments.

Dr. Brian Slomovitz, co-director of gynecologic oncology at Mount Sinai and study investigator, commented on the study findings. He stated that unlike many cancers, endometrial cancer incidents and mortality rates are escalating. In the U.S., endometrial cancer deaths have surpassed those caused by ovarian cancer, marking it as the deadliest gynecologic malignancy.

Despite recent strides introducing immunotherapy as standard care, more effective treatments for recurrent disease remain a pressing necessity. Slomovitz noted that if the complete data corroborate the announced results, understanding the survival benefits and toxicity profile will be crucial for sac-TMT’s application. An improvement in overall survival for recurrent cases holds significant potential for patients and their families.